Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, and PK of FTP-198 in Healthy Volunteers
NCT04687813Phase 1Completed
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
- Start
- Dec 2020
- Primary completion
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of FTP-198 in idiopathic pulmonary fibrosis (IPF) (3 cohorts), sponsored by Haisco Pharmaceutical Group Co., Ltd. Primary endpoint: Treatment Emergent Adverse Events. Started Dec 2020; status: completed.
02
Drugs
FTP-198
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT04687813.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04687813.